Sana Biotechnology (SANA) Liabilities and Shareholders Equity (2020 - 2026)

Sana Biotechnology's Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $373.6 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 16.14% year-over-year to $373.6 million; the TTM figure through Mar 2026 stood at $1.6 billion (down 25.28% YoY), while the FY2025 annual figure was $416.9 million, down 16.79% from the prior year.
• Liabilities and Shareholders Equity came in at $373.6 million for Q1 2026 at Sana Biotechnology, down from $416.9 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.0 billion in Q1 2022 to a low of $361.6 million in Q2 2025.
• A 5-year average of $634.3 million and a median of $618.7 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity decreased 8.78% in 2024 and tumbled 41.54% in 2025, its largest moves.
• Sana Biotechnology's Liabilities and Shareholders Equity stood at $822.7 million in 2022, then slumped by 31.29% to $565.3 million in 2023, then declined by 11.37% to $501.0 million in 2024, then retreated by 16.79% to $416.9 million in 2025, then fell by 10.39% to $373.6 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $373.6 million, $416.9 million, and $435.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison